Intervention not reported
False negativespeople incorrectly classified as not having isoniazid resistance · adults with pulmonary tuberculosis irrespective of rifampicin resistance (i.e. whether or not their rifampicin resistance status was…
1 finding from 1 review
Intervention not reported
True negativespeople without isoniazid resistance · adults with pulmonary tuberculosis irrespective of rifampicin resistance (i.e. whether or not their rifampicin resistance status was…
1 finding from 1 review
Treatment failure · Patients with presumed drug‐sensitive TB
1 finding from 1 review
Relapse · Patients with presumed drug‐sensitive TB
1 finding from 1 review
Death from any cause · Patients with presumed drug‐sensitive TB
Fluoroquinolone substitution for isoniazid in a standard six month… showed no clear difference in death from any cause compared with standard regimen (low certainty).
1 finding from 1 review
TB‐related death · Patients with presumed drug‐sensitive TB
Fluoroquinolone substitution for isoniazid in a standard six month… showed no clear difference in TB‐related death compared with standard regimen (low certainty).
1 finding from 1 review
Sputum culture conversion at 8 weeks · Patients with presumed drug‐sensitive TB
Fluoroquinolone substitution for isoniazid in a standard six month… showed no clear difference in sputum culture conversion at 8 weeks compared with standard regimen (low certainty).
1 finding from 1 review
Serious adverse events · Patients with presumed drug‐sensitive TB
Fluoroquinolone substitution for isoniazid in a standard six month… showed no clear difference in serious adverse events compared with standard regimen (low certainty).
1 finding from 1 review
One or more adverse event · Patients with presumed drug‐sensitive TB
1 finding from 1 review
Intervention not reported
Incidence of pulmonary tuberculosis in children with HIV infection ‐ isoniazid prophylaxis only · children with HIV infection aged 12 years and under
The intervention showed no clear difference in incidence of pulmonary tuberculosis in children with HIV infection ‐… (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality in children with HIV infection ‐ isoniazid prophylaxis only · children with HIV infection aged 12 years and under
The intervention showed no clear difference in mortality in children with HIV infection ‐ isoniazid prophylaxis only (low certainty).
1 finding from 1 review
Intervention not reported
Incidence of adverse events ‐ isoniazid prophylaxis only · children with HIV infection aged 12 years and under
The intervention showed no clear difference in incidence of adverse events ‐ isoniazid prophylaxis only (moderate certainty).
1 finding from 1 review
Intervention not reported
Completed preventive therapy with Isoniazid ‐ LHW supported self‐supervision or DOT compared with self‐supervision · patients with tuberculosis (TB) treatment
The intervention showed no clear difference in completed preventive therapy with Isoniazid ‐ LHW supported… (moderate certainty).
1 finding from 1 review
Active TB · HIV‐negative people at risk of TB infection1
It is very uncertain whether rifampicin changes active TB compared with isoniazid (very low certainty).
1 finding from 1 review
Adherence · HIV‐negative people at risk of TB infection1
It is very uncertain whether rifampicin plus pyrazinamide changes adherence compared with isoniazid (very low certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
Rifampicin plus pyrazinamide leads to higher treatment‐limiting adverse events compared with isoniazid (high certainty).
1 finding from 1 review
Hepatotoxicity · HIV‐negative people at risk of TB infection1
Rifampicin plus pyrazinamide probably leads to higher hepatotoxicity compared with isoniazid (moderate certainty).
1 finding from 1 review
Adherence6 · HIV‐negative people at risk of TB infection1
Rifampicin probably leads to higher adherence6 compared with isoniazid (moderate certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
It is very uncertain whether rifampicin changes treatment‐limiting adverse events compared with isoniazid (very low certainty).
1 finding from 1 review
Hepatotoxicity:13 Grade 3 and 4 toxicity · HIV‐negative people at risk of TB infection1
Rifampicin probably leads to lower hepatotoxicity:13 Grade 3 and 4 toxicity compared with isoniazid (moderate certainty).
1 finding from 1 review